Literature DB >> 7878696

Cyclosporin A monitoring in Australia: consensus recommendations.

R G Morris1, S E Tett, J E Ray.   

Abstract

Cyclosporin-A (CsA) therapeutic drug monitoring plays an integral role in therapeutic management of immunosuppressed patients, including those with organ transplants. This communication, prepared by an Australian team, presents recommendations for the routine monitoring of CsA, including blood sampling methodological approaches and interpretation of results generated. The consensus approach described is intended to address the diversity of attitudes to CsA monitoring demonstrated in a recent national survey of Australian laboratories that provide CsA analyses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7878696     DOI: 10.1097/00007691-199412000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Best practice in therapeutic drug monitoring.

Authors:  A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 3.  Target concentration strategy for cyclosporin monitoring.

Authors:  R G Morris
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 4.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

6.  Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Elizabeth A de Kort; Heleen S de Lil; Manita E J Bremmers; Lenneke F J van Groningen; Nicole M A Blijlevens; Gerwin Huls; Roger J M Brüggemann; Suzanne van Dorp; Walter J F M van der Velden
Journal:  PLoS One       Date:  2019-03-21       Impact factor: 3.240

7.  Comparison of architect I 2000 for determination of cyclosporine with axsym.

Authors:  Nafija Serdarevic; Lejla Zunic
Journal:  Acta Inform Med       Date:  2012-12

8.  A review on therapeutic drug monitoring of immunosuppressant drugs.

Authors:  Niloufar Mohammadpour; Sepideh Elyasi; Naser Vahdati; Amir Hooshang Mohammadpour; Jamal Shamsara
Journal:  Iran J Basic Med Sci       Date:  2011-11       Impact factor: 2.699

9.  Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.

Authors:  Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-07-28       Impact factor: 6.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.